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Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility
to malignant melanoma
A Lafuentel, R Molina2, J Palou3, T Castel3, A Moral4, M Trias4 and the MMM group*
'Institut de Salut Pu'blica, Universitat de Barcelona; 2Clinical Chemistry Department; Departments of3Dermatology and 4Surgery,
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Summary The isoenzyme Mu of glutathione S-transferase (GSTM1) is dominantly inherited, and the
prevalence of this isoenzyme in the population is about 60%. The lack of GSTMI has been linked with cancer
risk. The frequency of the phenotypes of this isoenzyme in melanoma (MM) patients (n = 197) is reported
here. A significantly higher proportion of individuals in the control group (n = 147) had measurable GSTMI
than MM patients (59.1% vs 42%, P = 0.002); there was a higher proportion ofpositive phenotypes in general
among women than among men. Odds ratio analysis indicated that individuals with this polymorphic variant
have an approximately 2-fold risk of developing these cancers. GSTMI phenotype distribution depends on
age, smoking habit and tumour pathology. A group of MM patients with dysplastic naevi was also studied.
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Epidemiological studies gathered over the last decade
indicate that malignant melanoma (MM) in humans is
related to both sun exposure habits and host factors. Ult-
raviolet (UV) irradiation leads to reactive oxygen species
(ROS) attack on target molecules such as lipids, proteins and
nucleic acids. Unrepaired damage to DNA appears to play a
central role in these carcinogenesis processes (Longstreth et
al., 1992). As a host genetic factor, dysplastic naevi (DN),
which are relatively distinct melanocytic lesions, can be
precursors of melanoma, and responsible for the tendency of
melanoma to run in families. Metabolic factors such as the
isoenzyme Mu of glutathione S-transferase (GSTM1) should
also be considered. GSTM1 has polymorphic expression, and
about half the population from various racial groups lack it
(Hussey et al., 1986). The enzyme detoxifies various car-
cinogenic electrophiles including epoxides, and it has
therefore been attributed a protective role against neoplasias
associated with smoking. Indeed, a major susceptibility to
lung (Seidegard et al., 1986), bladder and larynx cancer
(Lafuente et al., 1993) has been shown among smokers lack-
ing GSTM1.
When ROS damage DNA, the derived residues, which are
cytotoxic and cytostatic, are also substrates of GSTM1, sug-
gesting that these isoforms also have a role in the DNA
repair system (Ketterer and Meyer, 1989).
We therefore designed a study to determine whether
GSTM1 deficiency may confer susceptibility to malignant
melanoma (MM) on the basis of the antioxidant properties
of this isoenzyme against UV-derived ROS.
Materials and methods
A total of 197 white melanoma patients were recruited at the
Dermatology Department at the Hospital Clinic of Barcelona
in 1993. Ninety-three patients were men (mean age
53.0 ± 19.0) and 104 were women (mean age 51.06 ± 16.4).
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Skin pigmentation was evaluated by phototypes (Beitner et
al., 1990) which include type I (5%), type II (29%), type III
(49%) and type IV (17%). All had histologically proven
malignant melanoma and none had received prior chemo-
therapy or radiotherapy. A total of 147 unrelated white
control individuals without clinical or histological evidence of
cancer or inflammatory pathology were recruited from the
Surgery Department (82 men, mean age 51.6 ± 16.0; and 65
women, mean age 52.01 ± 19.8). Of the MM patients, 14 had
dysplastic naevi and were studied as a separate group for
which DN- and melanoma-free relatives were used as cont-
rols (n = 14).
Leucocytic GSTM1 was measured in whole blood samples
with an enzyme-linked immunoassay (ELISA) using affinity-
purified rabbit polyclonal antibody to human GSTM1
(MUKIT, Biotrin, Dublin, Ireland). Fifty microlitres of
haemolysed blood samples was mixed with 125fil of
phosphate-buffered saline (PBS) including 1% bovine serum
albumin (BSA) and 251l of Triton X-100. The remaining
procedure was as specified by the Mukit technical bulletin,
with the modification introduced by Brockmoller et al. (1993)
for the quantitative calibration of all assays: one batch of
electrophoretically pure GST class 1. protein (from Biotrin) is
added to one batch of venous blood (in PBS, 1:1) from a
GSTM1-deficient individual.
Standard curves were made up between 0.010 and
50 igml1' in whole blood. Individuals with enzyme levels
below 1 jgml-' were considered to be deficient in GSTM1.
The mean of GSTM1 cross-reacting proteins for negative
individuals was 0.123 jig ml-'.
Leucocyte and differential counts were normal in all sub-
jects included.
Immunohistochemistry studies were performed with puri-
fied rabbit polyclonal antibody to GSTM1 (BioGenex, San
Ramon, CA, USA). The rest of the procedure for visualisa-
tion of antibody-reacting regions was performed using the
biotin-streptavidin-alkaline phosphatase method (Multilink,
BioGenex) with fast red chromogen for visualisation.
Odds ratios and confidence intervals (CIs) were used to
analyse the frequencies of phenotypes; the corresponding x2
values were calculated.
Results
Data show a bimodal distribution of GSTM1 content, posi-
tioning the antimode at 1 yg ml-', thus confirming the
previously established antimode described by Brockmoller et
al. (1993). The mean GSTM1 content for positive controls
was 3.16± 1.33fgml-' or 1.93 ±1.14 g/10-6 lymphocytesGlutathione Stransferase Mu and melanoma
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Table I Proportion of individuals expressing GSTMI with and without melanoma
Melanoma No melanoma OR 95% CI P
Men 34/89 (0.382)a 45/82 (0.548) 1.96 1.35-2.56 0.02
Women 43/94 (0.457) 42/65 (0.646) 2.1 1.45-2.74 0.01
Men and women 77/183 (0.420) 87/147 (0.591) 1.99 1.56-2.41 0.002
'Number with GSTM1/total number examined (ratio ofindividuals with GSTMI).
Table II Proportion of melanoma patients expressing GSTMI in
subgroupsa based on tumour characteristics
Women Men Women and men
Histological typeb
SSM 32/69 (0.463)c 18/50 (0.360) 50/119 (0.420)
LMM 3/7 (0.428) 2/6 (0.333) 5/13 (0.384)
ALM 3/5 (0.600) 4/8 (0.500) 7/13 (0.538)
NM 4/15 (0.266) 6/18 (0.333) 10/33 (0.303)
TU 1/2 (0.500) 4/7 (0.571) 5/9 (0.555)
Clark classification
Grade I 7/14 (0.500) 3/5 (0.600) 10/19 (0.526)
Grade II 8/19 (0.421) 6/13 (0.500) 14/32 (0.437)
Grade III 21/44 (0.477) 17/46 (0.369) 38/90 (0.422)
Grade IV-V 8/20 (0.400) 7/24 (0.291) 15/44 (0.340)
Breslow index (mm)
< 1.5 35/68 (0.514) 22/57 (0.385) 57/125 (0.456)
, 1.5 9/26 (0.346) 10/25 (0.400) 19/51 (0.372)
aSubgroups include DN-MM patients and exclude some cases in
which it was not possible to obtain this information. bSSM, superficial
spreading melanoma; LMM, lentigo maligna melanoma; ALM, acral
lentiginous melanoma; NM, nodularmelanoma; TU, type unclassified.
CNumber with GSTM1/total number examined (ratio of individuals
with GSTMI).
and for MM patients 3.37 ± 1.02 jig ml-' or 2.13 ± 1 fig 10-6
lymphocytes.
A significantly higher proportion of the control individuals
had GSTM1 (59.1%) than melanoma patients (42%; x2 test,
P = 0.002). When subgroups by sex were considered, propor-
tions were maintained, although more individuals with
positive phenotype were found among women in both
groups. The overall odds ratio calculated was 1.99 (95% CI
1.56-2.41) (Table I).
Despite the limited number of cases, the frequency of
positive GSTM1 was lower in DN-MM patients (35.7%), but
also in DN controls (42.8%). In subgroups based on the skin
phototype, smoking habit or age at diagnosis, proportions
showed no modifications. The distribution of GSTM1 based
on histological subtypes of MM showed a trend towards a
more common null phenotype in nodular melanoma than in
superficial spreading melanoma (the most frequent subtypes),
especially in women. Subgroups according to the depth ofthe
tumour penetration show that the incidence of the null
phenotype is higher when disease presents in a more aggres-
sive form (grade IV-V, Breslow>, 1.5 mm) (Table II).
No difference in GSTM1 content in positive patients was
found between any of the subgroups established.
Immunohistological studies on four of the eight patients
a b
Figure I (a) GSTMI showing staining of normal melanocytes in the basal layer, leaving the rest ofepidermis practically unstained
(x 330). (b) GSTMI showing moderate staining in MM cells (x 165).Glutathione S-transferase Mu and melanoma
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examined revealed that the antibody to GSTM1 stained the
normal melanocytes strongly (in the basal layer), whereas the
remaining epidermal cells stained weakly. Cytoplasm and
nuclei in melanoma stained moderately (Figure 1). One hun-
dred per cent correlation was found with ELISA blood
results.
Discussion
Excessive UV irradiation, with consequent ROS attack on
target molecules such as DNA, appears to be one of the
major causes ofmelanoma. GSTM1 may be important in the
repair of DNA since it is present in the normal melanocytes
in both cytoplasm and nuclei, and because it may efficiently
detoxify peroxides arising in DNA (Ketterer and Meyer,
1989).
Various authors have reported that GSTM1 is almost
non-existent in human epidermis (Blacker et al., 1991; Camp-
bell et al., 1991; Raza et al., 1991; Singhal et al., 1993).
Minimal amounts of the Mu class GSTs are present in
human skin samples, as shown by Western blot analysis or
immunohistological staining in the human epidermis, where
most cells are keratinocytes. Hence, the risk conferred by the
presence or absence of GSTM1 in keratinocytes may also be
minimal. However, in melanocytes the opposite is true. Nor-
mal melanocytes presented positive GSTM1 staining by
immunohistological techniques in the study by Campbell et
al. (1991), and this was also confirmed here, which suggests
that this isoenzyme is important to the host defence of these
cells.
GSTM1 deficiency has been studied in relation to lung
(Seidegard et al., 1986), bladder and larynx cancer (Lafuente
et al., 1993) and in individuals with multiple skin cancers
(Heagerty et al., 1994), but this is the first time that this
deficiency has been related to melanoma as single tumour.
Our results confirm the importance of phase II enzymes
such as GSTM1. Individuals with genetic absence of this
isoenzyme appear to be more susceptible to these neoplasms.
It also seems that these neoplasms appear in a more aggres-
sive form, since certain negative clinical aspects, such as age
at diagnosis, histological types and, especially, the depth of
the tumour penetration, tend to depend on the presence of
this isoenzyme (Lafuente et al., 1993).
Epidemiological studies suggest that host factors such as
fair complexion and a tendency to sunburn rather than tan
could be aetiopathogenic factors in malignant melanoma.
The distribution of phototypes in MM patients is similar to
distribution reported elsewhere (Elwood et al., 1986). How-
ever, compared with metabolic risk factors, skin phototypes
seem to be independent of GSTM1 phenotype.
Smoking has also been suspected to be related to MM risk
(Aubry and McGibbon, 1985); in fact, electrophiles from
tobacco smoke could increase the toxicity of ROS, as has
been extensively proposed in the literature (Kensler and
Trush, 1985; Trush and Kensler, 1991). However, in contrast
to what is observed in other tumours (Seidegard et al., 1986;
Lafuente et al., 1993), the distribution ofGSTM1 phenotypes
is similar in smokers and in non-smokers, suggesting that in
this case GSTM1 protection is not related to tobacco smoke
exposure.
Therefore, it can be concluded that the protective role of
GSTM1 operates even in neoplasms that have no direct
relationship with tobacco smoke exposure. This provides
indirect evidence of the considerable importance of GSTM1
in antioxidant defence, and in the DNA repair system.
Abbreviations: DN, dysplastic naevi; GSTM1, glutathione S-
transferase Mu; MM, malignant melanoma; ROS, reactive oxygen
species.
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